RxDoctor Payments Data

Garvin Chastain, MD

Internal Medicine · Cleveland, TNNPI 1518933829

Payments from drug & device makers

$7,349in general payments, 2019–2025

Across 455 payments — averaging $16.15 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$1K
  • Johnson & Johnson$508
  • Lilly USA, LLC$493
  • AstraZeneca$481
  • AbbVie$381
  • Boehringer Ingelheim$375
  • plus $4K from 44 others

What the payments were for

  • Food & beverage$7,322100%
  • Education$270%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$7,349 in reported general payments places this provider in the 90th percentile of 2,216 internal medicine providers in Tennessee.

See all internal medicine providers in Tennessee

Medicare billing

Part B allowed, 2024
$132,854
Medicare patients
470
Services billed
1,841

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide203$212,003
EliquisApixaban191$151,048
JardianceEmpagliflozin84$99,409
MounjaroTirzepatide48$48,764
TrulicityDulaglutide25$46,969
GlyxambiEmpagliflozin/Linagliptin29$36,504
SantylCollagenase Clostridium Hist.56$33,583
XareltoRivaroxaban31$32,549
Toujeo SolostarInsulin Glargine,hum.Rec.Anlog49$30,099
Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog17$22,150
Trelegy ElliptaFluticasone/Umeclidin/Vilanter13$18,482
LinzessLinaclotide19$17,609
MyrbetriqMirabegron32$16,731
Trijardy XrEmpaglifloz/Linaglip/Metformin11$16,201
TradjentaLinagliptin11$15,275

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$1,423$223,952216 claims
Boehringer IngelheimJardiance, Glyxambi, Trijardy Xr, Tradjenta, Synjardy Xr$375$193,794178 claims
PfizerEliquis, Nurtec Odt$277$161,332202 claims
Lilly USA, LLCMounjaro, Trulicity$493$95,73473 claims
Smith+NephewSantyl$350$33,58356 claims
Johnson & JohnsonXarelto$508$32,54931 claims
MerckJanuvia, Janumet, Janumet Xr$23$22,78051 claims
GSKTrelegy Ellipta$122$18,48213 claims
AbbVieLinzess$381$17,60919 claims
Astellas Pharma US IncMyrbetriq$96$16,73132 claims
Sumitomo Pharma America, Inc.Gemtesa$105$9,70519 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 2,216 internal medicine providers in Tennessee.

Other internal medicine in Cleveland

See the full list for Tennessee

Where these figures come from

Is this you, or does something look wrong? →